Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer

BMC Cancer(2021)10.1186/s12885-021-08366-7Source: DataRank Database

Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer is a research paper published in BMC Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 20 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access20 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 1.38)OA: goldTopics (97)Linked Datasets (4)DataCite Reuse (4)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

María del Mar Maldonado ORCID,Julia Medina‐Velázquez,Angel Luis Troche‐Torres,Luis Velázquez,Nilmary Grafals‐Ruiz ORCID

Live enrichment

PubMed:34074257 PMC:PMC8170972 OpenAlex:https://openalex.org/W3165012964

U.S. Army Medical Research Acquisition Activity

Grant: W81XWH2010041

Susan G. Komen

Grant: OG170023

National Institute of General Medical Sciences

Grant: P20 GM103475

National Institutes of Health

Grant: NIH/NIGMS SC3GM094824

National Institute of General Medical Sciences

Grant: G12RR03051

Foundation for the National Institutes of Health

Grant: R25GM061838

NIGMS NIH HHS

Grant: SC3 GM084824

National Institutes of Health

Grant: 5R25GM061838-22

NIGMS RISE Program at the UPR Medical Sciences Campus

National Institutes of Health

Grant: 2G12RR003051-21

SUPPLEMENT FOR RENOVATION OF ANIMAL FACILITIES AT INSTITUTE OF NEUROBIOLOGY

National Institutes of Health

Grant: 5P20GM103475-16

Advancing Competitive Biomedical Research in Puerto Rico

National Institutes of Health

Grant: 1S10RR013039-01

MICROPLATE SCINTILLATION/LUMINESCENCE/FLOUR COUNTER

Puerto Rico Science, Technology and Research Trust

FWCI

1.38

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-021-08366-7

GOLDhttps://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-021-08366-7

publisherhttps://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-021-08366-7

publisherhttps://link.springer.com/content/pdf/10.1186/s12885-021-08366-7.pdf

publisherhttps://link.springer.com/article/10.1186/s12885-021-08366-7/fulltext.html

Fields of Study

HER2/EGFR in Cancer ResearchProtein Kinase Regulation and GTPase SignalingLung Cancer Treatments and MutationsMedicine03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsApoptosisBreast NeoplasmsCarbazolesCell Line, TumorDrug Resistance, NeoplasmDrug Screening Assays, AntitumorErbB ReceptorsFemaleGain of Function MutationGefitinibGene Expression Regulation, NeoplasticHumansLapatinibMAP Kinase Signaling SystemPoint MutationProtein Kinase InhibitorsPyrimidinesErb-b2 Receptor Tyrosine KinasesSpheroids, CellularUp-Regulationrac GTP-Binding Proteins

MeSH Terms

Gain of Function MutationGefitinibLapatinibAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarbazolesDrug Screening Assays, AntitumorFemaleHumansPyrimidinesUp-RegulationGene Expression Regulation, NeoplasticApoptosisPoint MutationErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-2Spheroids, CellularDrug Resistance, Neoplasmrac GTP-Binding ProteinsMAP Kinase Signaling SystemCell Line, TumorProtein Kinase InhibitorsErbB Receptors

Keywords

LapatinibGefitinibSKBR3Targeted therapyCancer researchProtein kinase BMedicineMAPK/ERK pathwayEGFR inhibitorsBreast cancerPI3K/AKT/mTOR pathwayErbBCombination therapyCancerEpidermal growth factor receptorSignal transductionInternal medicineBiologyTrastuzumabCell biologyTherapy ResistanceTyrosine Kinase Inhibitors (Tkis)Ehop-016Mbq-167Rac InhibitorsMAP Kinase Signaling SystemCarbazolesApoptosisBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesCell Line, TumorSpheroids, CellularAntineoplastic Combined Chemotherapy ProtocolsHumansPoint MutationProtein Kinase InhibitorsRC254-282Neoplasms. Tumors. Oncology. Including cancer and carcinogensErbB ReceptorsGene Expression Regulation, NeoplasticPyrimidinesDrug Resistance, NeoplasmGain of Function MutationFemaleDrug Screening Assays, AntitumorResearch Article

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer

10.6084/m9.figshare.14715028.v1figshare

Additional file 1 of Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer

10.6084/m9.figshare.14715028figshare

Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer

10.6084/m9.figshare.c.5448103figshare

Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer

10.6084/m9.figshare.c.5448103.v1figshare